We are happy to announce our plans for a full product rebranding with the Sebia name.

Following the acquisition of ZEUS Scientific by Sebia in October 2022, we are delighted to inform you that as of January 1, 2024, ZEUS Scientific is operating as Sebia Autoimmune & Infectious Diseases. Read on to find out more!

Coming to AACC?

ZEUS Scientific is now part of Sebia!  There are so many ways you can connect with us to learn about Sebia solutions for your laboratory.  Check them out here and join us!

ZEUS Scientific is now part of Sebia.  Meet us atthe Sebia Booth #1300 during the AACC Expo to hearabout Sebia's specialty diagnostics product offerings.

ZEUS Scientific proudly supports Lyme Disease Awareness Month and is committed to providing industry-leading products to aid in its diagnosis.  We also realize prevention is critical in the battle against Lyme disease. 

The discovery of the bacterium responsible for Lyme disease and how it is carried specifically by deer ticks provides us with valuable information to help prevent Lyme disease. Proactive Lyme disease prevention and testing once you identify a tick or have symptoms is the key.

May is Lyme Disease Awareness Month, an important reminder for us all to be proactive to protect ourselves against Lyme disease, know the symptoms and if suspected, get tested and treated early.

ZEUS Scientific is here to lend a hand in your busy laboratory with the SP30, our easy-to-use and efficient walk-away benchtop instrument for IFA slide processing.  Increase productivity in your laboratory with the built-in, automatic cover slipping feature of the SP30.

Introducing the dIFine 30 System

A powerful partnership at your fingertips: Pair our next-generation digital IFA imaging and interpretation system with our easy-to-use and efficient walk-away benchtop instrument for IFA slide processing ...including cover slipping!

Still using STTT to detect Lyme disease? See who you could be missing with ZEUS Borrelia MTTT^®.

In a recent study, ZEUS Borrelia MTTT-2^® detected nearly double the cases of early Lyme disease compred to STTT.  How long until you miss someone you know?

Get to know ZEUS Scientific and ourindustry-leading menu of testing solutions. Check out our broad menu of test systems for autoimmune and infectious diseases.

A multicenter clinical evaluation of ZEUS Scientific’s Modified Two-Tiered Testing (MTTT) algorithms was recently published in the Journal of Clinical Microbiology.*  The clinical evaluation included testing of 376 archived samples as well as 2,932 prospective samples collected at three clinical laboratories.  Check out the findings about ZEUS Borrelia MTTT®!

A reminder that ZEUS Scientific offices and manufacturing facilities will be closed on Monday, December 26 for Christmas.  While our offices are closed, our technical service team will be available to support you from 7:45am until 5:15pm EST.

With only 15 days left of 2022, now is the time to get ready for the 2023 Lyme disease season by implementing ZEUS Scientific’s Borrelia Modified Two-Tiered Testing (MTTT) algorithm.  Do not get left behind in 2023 using an outdated Lyme disease testing algorithm.  Let the experts at ZEUS assist your laboratory and replace difficult-to-read immunoblots all together with the first FDA-cleared Borrelia MTTT algorithm method of testing for Lyme disease.

With just one click on the ZEUS dIFine digital immunofluorescence system, you get instant access to the built in ZEUS ANA HEp-2 Pattern Atlas, a reference library of ZEUS ANA HEp-2 slide pattern images that align with ICAP nomenclature, improve standardization and increase confidence in your results.

Here at ZEUS Scientific, we have a lot to be thankful for.  We are most thankful for the support we receive from you - our customers, our partners, our employees, and our friends.  Thank you for choosing ZEUS.

The ZEUS dIFine® digital immunofluorescence system is the next generation in IFA imaging and pattern recognition. dIFine is an automated digital scanner with intelligent software, designed to acquire, analyze, display and store digital images of ZEUS HEp-2 IFA slides.

Typically, during ANA screening, a large proportion of results are negative.  ZEUS dIFine saves you time by allowing you to quickly batch, review and validate negative results, allowing you to focus your attention on the positives.

Locating mitotic cells is typically a time-consuming process and is required to confirm many ANA HEp-2 patterns. The ZEUS dIFine Digital Immunofluorescence System allows you to identify and locate mitotic cells with one click, allowing for easy pattern validation.

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announces the acquisition of  ZEUS Scientific, an In Vitro Diagnostic (IVD) company based in New Jersey (US) specialized in autoimmune and infectious diseases technologies. Financial terms of the agreement are undisclosed.

A multicenter clinical evaluation of ZEUS Scientific’s Modified Two-Tiered Testing (MTTT) algorithms was recently published in the Journal of Clinical Microbiology.  The clinical evaluation included testing of 376 archived samples as well as 2,932 prospective samples collected at three clinical laboratories.

Happy Labor Day!

ZEUS Scientific is a pioneer in clinical diagnostics providing solutions for autoimmune disease and infectious serology for over 45 years.

Our assays are formatted using multiple technologies to provide any size laboratory with choice and flexibility for reporting results. We also ensure convenient, cost-effective automation options are available.

Lyme disease immunoblots have never been a lab favorite. Now there is a better algorithm that eliminates the need for them:ZEUS Borrelia MTTT®

ZEUS Scientific IFA ANA HEp-2 Slides are the clear choice for your IFA ANA testing needs.  Our slides are prepared using a proprietary cell fixation process that uses natural, unaltered antigens to provide crisp, clear images that you can count on!  Pair them with the FDA-cleared dIFine®* Digital Immunofluorescence System, our new imaging and pattern recognition system, to automate the entire IFA process. See for yourself!

Meet ZEUS Scientific at the 2022 AMLI Conference, August 12-15th in Salt Lake City.

Happy Independence Day from the ZEUS Scientific family

ZEUS Scientific is a pioneer in clinical diagnostics providing solutions for autoimmune disease and infectious serology for over 45 years. Visit Booth #2845 to learn more about our solutions for your laboratory.

Thank you for joining us for this Lyme Disease Awareness Month Educational Series. We hope you have benefited from the information provided either as a reminder for this Lyme disease season or as an opportunity to learn something new.  In this final Lyme Disease Awareness Series installment, we focus on diagnosis and treatment options.

In the final week of Lyme Disease Awareness Month, let's focus on prevention by understanding the risks & actions to take to prevent Lyme disease.

We continue our series during this year’s National Lyme Disease Awareness Month with a focus on the history of Lyme disease and how Lyme disease testing has evolved to improve early detection. Learn how Lyme disease was first identified and ZEUS’s role in moving testing forward.

May is Lyme Disease Awareness Month, an important reminder for us all to be proactive to protect ourselves against Lyme disease, know the symptoms and if suspected get tested early using the newest and most accurate testing algorithm. To help raise awareness, we will be sharing information on Lyme disease, including key facts, testing, prevention, diagnosis and the importance of timely treatment.

The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific’s  dIFine digital immunofluorescence system for use with ZEUS’s ANA HEp-2 indirect fluorescent antibody (IFA) assay.

The FDA-cleared ZEUS dIFine digital immunofluorescence system is the next generation in IFA imaging and pattern recognition.  An automated digital scanner with intelligent software, ZEUS dIFine quickly delivers positive/negative results and has been programmed to suggest eight common ANA patterns*:  homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal) and cytoplasmic (mitochondrial).

Typically, during ANA screening, a large proportion of results are negative.  ZEUS dIFine saves you time by quickly allowing you to batch, review and validate negative results allowing you to focus your attention on the positives.

Change is easier than you think!

Are you still following STTT and using immunoblots or sending out to have them run in another laboratory?  If you are ready to make the change to a more accurate Lyme disease testing algorithm, let us help you convert to ZEUS Borrelia MTTT!

As a pioneer in indirect fluorescent antibody (IFA) technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976. With over 45 years of expertise in autoimmune serology, ZEUS ANA HEp-2 slides are well known as the clear choice.

Do you have questions? ZEUS has answers.

Let us provide you with a thorough understanding of transitioning from the Standard Two-Tiered Testing (STTT) algorithm to the first FDA-cleared Modified Two-Tiered Testing (MTTT) algorithms.Join our monthly Lyme disease testing sessions to have your questions answered.  Sign up today for your personal expert consultation.  Next session is February 16, 2022, from 9am to 4pm EST.

There are over 25 ANA HEp-2 cell patterns classified and named by the International Consensus on Antinuclear Antibody Patterns (ICAP).  Some are common and more easily recognized; others are not.  With ZEUS diFine you get our 45+ years of expertise in your laboratory with the built in ZEUS ANA HEp-2 Pattern Atlas that is accessible with one click.

Wishing you all a happy and safe Holiday Season and a prosperous New Year!

We know seeing is believing.  Let us give you a closer look at one of the many user-friendly features packed into the ZEUS dIFine System: the mitotic gallery. 

This Thanksgiving, we are filled with hope and gratitude, realizing that we continue to stand tall because of the continuous support we receive from you - our customers, our partners, our employees, and our friends.  For that we are forever grateful.

Does your SARS-CoV-2 antibody test detect antibodies produced from natural infection and vaccination?
The ZEUS ELISA SARS-CoV-2 Antibody Test Systems' dual antigen design can!

ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co.
Could Hold the Clue to Creating Better Treatments for Rheumatoid Arthritis

As a pioneer in indirect fluorescent antibody (IFA) technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976. 

Meet the next generation in IFA imaging and pattern recognition, the ZEUS dIFine® digital immunofluorescence system. dIFine is an automated digital scanner with intelligent software, it is designed to acquire, analyze, display and store digital images of ZEUS HEp-2 IFA slides.* 

Want to improve your laboratory’s detection of early Lyme disease (stage 1 and stage 2) by up to 30%?There is a catch!

The expertise that ZEUS Scientific has gained from over 45 years of developing and manufacturing diagnostic tests was instrumental in creating the unique dual antigen design of the ZEUS ELISA SARS-CoV-2 Antibody Test Systems.  Utilizing these tests with the Dynex AGILITY® fully automated ELISA system provides you with a powerful and simple combination for your testing needs.  As the world continues to fight the COVID-19 pandemic, SARS-CoV-2 antibody testing remains an important tool.

As our country slowly starts to get back to normal, we remember and cherish the high price of freedom.  We appreciate you making the choice to be our customer, our partner, our employee and our friend.

Happy Independence Day!

Thank you for joining us for this Lyme Disease Awareness Month Educational Series. We hope you have benefited from the information provided either as a reminder for this Lyme disease season or as an opportunity to learn something new.  In this final Lyme Disease Awareness Series installment, we focus on diagnosis and treatment options.

With National Lyme Disease Awareness Month behind us, let's focus on prevention. 

The discovery of the bacterium responsible for Lyme disease and how it is carried specifically by deer ticks provides us with valuable information to help prevent Lyme disease. Proactive Lyme disease prevention and testing once you identify a tick or have symptoms is the key.

ZEUS Scientific has received Emergency Use Authorization (EUA) for additional automation claims from the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the qualitative detection of IgG antibodies to the SARS-CoV-2 virus in human serum and plasma.  The ZEUS ELISA SARS-CoV-2 IgG Test System assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein that detects immune responses that other antibody tests may miss.

We continue our series during this year’s National Lyme Disease Awareness Month with a focus on the history of Lyme disease and how Lyme disease testing has evolved to improve early detection.

ZEUS Scientific has been granted by the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its in vitro ELISA diagnostic test for the qualitative detection of total antibodies to the SARS-CoV-2 virus in human serum and plasma. ZEUS has been producing and shipping the ELISA SARS-CoV-2 Total Antibody Test System since June 2020 and has steadily increased production capabilities to keep up with the growing demand. Achieving EUA approval was the next step in ZEUS’s commitment to deliver superior quality COVID-19 antibody detection devices.  The ZEUS ELISA SARS-CoV-2 Total Antibody Test System joins our previously EUA-approved ZEUS ELISA SARS-CoV-2 IgG Test System.

May is Lyme Disease Awareness Month, an important reminder for us all to be proactive to protect ourselves against Lyme disease, know the symptoms and if suspected get tested early using the newest and most accurate testing algorithm. To help raise awareness, we will be sharing information on Lyme disease, including key facts, testing, prevention, diagnosis and the importance of timely treatment.

Are you still using immunoblots for your 2nd tier Lyme disease testing?  Join the trend and eliminate blots altogether.

Immunoblots were never a lab favorite.  In fact, most labs do not bother with them in-house and choose the costly send out option.  Now there is a better way. Say good-bye to immunoblots and leave behind immunoblot insensitivity, subjectivity and all the related technical challenges while improving accuracy and boosting overall efficiency in your laboratory with a simple workflow.

Now is the perfect time to partner with ZEUS Scientific for your SARS-CoV-2 antibody testing, and put the power of our dual antigen design to work in your laboratory with full automation right out of the box.

Lyme disease is curable.  The faster it is diagnosed and treated, the better the outcome for the patient.  Missing a Lyme disease diagnosis can lead to long-term health repercussions for patients.  Now is the perfect time to make the benefit-driven promise of a Borrelia MTTT algorithm a reality in your laboratory.

The ZEUS ELISA SARS-CoV-2 Test Systems are designed to detect antibodies against both the Nucleocapsid protein and the Spike protein S1-RBD and is optimized for superior sensitivity and specificity.

Are you still using immunoblots or the discontinued MarDx® Lyme disease Western blot?  If you are trying to figure out your transition plans, let us help convert to a more accurate Lyme disease testing algorithm!

Making the switch to the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm gives you improved detection of early Lyme disease, allows you to replace outdated Lyme disease immunoblots, and increases overall lab workflow and efficiency.

Do you know someone who is wondering if they had COVID-19 and were asymptomatic? Are they thinking “Did I have COVID-19 and not realize it, was that short term cough due to allergies or did I have mild symptoms for COVID-19?”

With less than 30 days left of 2020, now is the time to get ready for the 2021 Lyme disease season by implementing ZEUS Scientific's Borrelia Modified Two-Tiered Testing (MTTT™) algorithm.

Help with the fight against antibiotic resistance. Accuracy matters.Early detection and appropriate treatment can make a world of difference. 

See the Quality Only ZEUS Can Deliver!

With over 40 years of experience, ZEUS Scientific continues to be a pioneer in immunofluorescence assay (IFA) technology delivering quality and expertise in ANA HEp-2 IFA testing that laboratories have relied on since 1978.

Antibody testing provides valuable information to help stop the spread of the virus.

Learn about the history of Lyme disease and ZEUS’s Borrelia MTTT™ algorithm that led to a paradigm shift in Lyme disease testing

Join Us October 29th at 10am EST

ZEUS Scientific announced today, October 7, 2020 the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its in vitro ELISA diagnostic test for the qualitative detection of IgG antibodies to the SARS-CoV-2 virus in human serum and plasma.  ZEUS has been producing and shipping the ELISA SARS-CoV-2 IgG Test System since early June 2020 and has steadily increased production capabilities to keep up with the growing demand.  Achieving EUA approval was the next step in ZEUS’s commitment to deliver superior quality COVID-19 antibody detection devices.

Missed the feature on the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm on Lifetime’s Access Health?  Here’s your chance to see what everyone is talking about!  Watch as Host Ereka Vetrini and Dr. Raymond Dattwyler, M.D. discuss the history of Lyme disease testing, and the importance of the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm, the breakthrough in early Lyme disease testing.

Are you ready to learn about a faster, easier, and more accurate way to test and diagnose early Lyme disease? Then tune in TOMORROW at 7:30am EDT* to Lifetime Network’s Access Health!

Be sure to tune in to Lifetime network’s Access Health on September 25th, 2020 which will provide useful information on Lyme disease, with an emphasis on symptoms and the importance of testing featuring the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm.

As the game continues to change in Lyme disease diagnosis, the MarDx™ Lyme Western blot assays are being discontinued by the manufacturer.  Do not risk being left behind using an outdated Lyme disease testing algorithm.  Stay up to date with ZEUS Borrelia MTTT™ algorithm, the only FDA cleared MTTT algorithm that eliminates the need for the confirmatory immunoblot test AND improves early Lyme Disease diagnosis.

ZEUS dIFine^® is the next generation in IFA imaging and pattern recognition system.  An automated digital scanner with intelligent software, it is designed to acquire, analyze, display and store digital images of ZEUS HEp-2 IFA slides*.  ZEUS is taking your ANA IFA testing to the next level by pairing our top tier IFA ANA HEp-2 products with our dIFine™ system and quickly delivering positive/negative results and interpretation of 8 distinct ANA HEp-2 patterns.

The word is getting out regarding how ZEUS Borrelia MTTT™ is improving early Lyme Disease diagnosis.  Lifetime network will feature the only FDA cleared Borrelia Modified Two-Tiered Testing (MTTT) algorithm on their Access Health series scheduled to air on September 25th and October 3rd, 2020.

The best slides deserve the best in class automation.  We have completed the next step by submitting the ZEUS dIFine^® to the FDA last month.  We are taking your ANA IFA testing to the next level by pairing our IFA ANA Hep-2 with our dIFine^® system.

ZEUS Borrelia MTTT™ is a simpler, more cost effective, faster and better way to more accurately detect Lyme disease than using immunoblots. This updated algorithm detected up to 30% more positive patients in acute early Lyme disease, the critical time to correctly identify and treat!

While the world continues to deal with the COVID-19 pandemic, ZEUS recognizes the challenges facing resource strained labs as pre-pandemic test volumes rebound while absorbing the additional COVID-19 testing demands.  ZEUS offers two SARS-CoV-2 antibody test systems which seamlessly integrates with our broad range of ELISA assays, spanning across autoimmune and infectious disease testing.

ZEUS has completed extensive performance testing of all of our devices using the same cohorts (total n=365) of clinically characterized patient samples.

The ZEUS Borrelia MTTT™ algorithm was recently featured on the July 8th, 2020 NBC News Center Maine evening News. Read about it here!

ZEUS Scientific Is a Proud American CompanyDoing our Part in the Fight Against COVID-19

 We have a long history of developing, manufacturing and delivering IVD kits for infectious and autoimmune disease testing.  With over 125 FDA cleared assays in our menu, we continue to apply our expertise of developing tests to detect human antibodies to a number of different viruses including SARS-CoV-2.  For decades, laboratories have trusted ZEUS and now is the time to maintain confidence in ZEUS as we all continue the battle against the COVID-19 pandemic and SARS-CoV-2 virus.

We now offer 3 separate SARS-CoV-2 antibody test systems across two methodologies testing for IgG, IgG/IgM and IgG/IgM/IgA which can be utilized individually or combined to implement an orthogonal testing algorithm for positive results to increase positive predictive value, all from the same manufacturer.

ZEUS Scientific announced today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of Total (IgG, IgM, IgA)  antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now. 

ZEUS Rapid SARS-CoV-2 IgM/IgG has been validated according to FDA guidelines established for serological assays, meeting the criteria to be distributed to where it is needed most. In response to the many inferior SARS-CoV-2 antibody tests flooding the market, the U.S FDA strengthened their data requirements to obtain an Emergency Use Authorization (EUA) for a COVID-19 antibody test.  ZEUS immediately reacted by conducting a USA study of clinically characterized specimens that confirms the superior performance of our Rapid SARS-CoV-2 IgM/IgG Test System.  ZEUS Scientific has heard your requests for help and is committed to providing quality easy-to-use solutions that will help address the public health threat posed by COVID-19.

ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its in vitro ELISA diagnostic test for the semi-quantitative detection of IgG antibodies to the SARS-CoV-2 (novel 2019 Coronavirus) in human serum and plasma. ZEUS has notified FDA that the test has been validated according to their guidelines established for serological assays, meeting the criteria to be distributed and is available now.

In this time of crisis, we are here to help. For over 40 years ZEUS Scientific has developed, manufactured and sold in vitro diagnostic test kits for infectious and autoimmune disease testing. We have allocated the majority of our resources to produce serological antibody tests to combat the SARS-CoV-2 virus.  For decades, many of our products were built to detect human antibodies to a number of different viruses and we have now applied that knowledge to help in the fight with the COVID-19 pandemic.

Specificity Matters!

ZEUS Rapid SARS CoV-2 IgM/IgG Antibody Test System delivers with over 98% Specificity and no demonstrated cross reactivity to other coronaviruses.

COMING SOON: ZEUS ELISA SARS CoV-2 Test System!

• Do you have serological samples from confirmed PCR-positive COVID-19 patients?
• Can we collaborate to validate assay performance for SARS-CoV-2 antibody testing?

ZEUS Rapid SARS-CoV-2 IgM/IgG is validated, in stock and available to ship immediately.

On April 28th, 2020 ZEUS Scientific officially notified the U.S. FDA that it has validated the ZEUS Rapid SARS-CoV-2 IgM/IgG Test System and intends to begin distributing this product to laboratories.

ZEUS Scientific announces today the submission for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its rapid, in vitro diagnostic test for the qualitative detection of IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 Coronavirus).

In this troubled time, know you can count on the ZEUS Scientific team to be here for you.  We remain fully operational to meet all your laboratory testing needs. Read on to learn about our COVID-19 response.

Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared today are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test. 

ZEUS Borrelia MTTT™ algorithm has been shown to significantly improve the detection of early Lyme disease with increased sensitivity over the current standard two-tiered testing (STTT) algorithm.

ZEUS Scientific has announced that as of January 1st, 2019, ZEUS will assume all sales, marketing and support functions for all ZEUS IFA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.

Dynex Technologies has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ) enabling ZEUS to sell Dynex instruments to the global clinical market. This new direct partnership builds on the long standing relationship between both companies with Dynex Technologies’ industry proven DS2®, DSX® and Agility® automated ELISA instrumentation and ZEUS Scientific’s broad range of ZEUS ELISA™ Test Systems which use common reagents and universal protocols across a diverse autoimmune and infectious disease menu.

ZEUS Scientific has announced that as of February 1st, 2018, ZEUS will assume all sales, marketing and support functions for all ZEUS ELISA™ Test Systems in the United States, its territories and possessions and Puerto Rico. On this date, laboratories, hospitals, universities and any other United States based facilities can begin to order these products directly from ZEUS Scientific. For more information on how to contact ZEUS Scientific visit: www.zeusscientific.com/contact-us.

ZEUS Scientific announces the launch of ZEUS ELISA Parvovirus B19 IgG and IgM Test Systems, following receipt of Premarket Approvals (PMA) from the U.S. Food and Drug Administration (USFDA). ZEUS ELISA Parvovirus B19 Test Systems are the latest addition to the company’s market leading range of infectious disease diagnostic solutions with seamless integration into the ZEUS ELISA menu of Test Systems. These test systems feature universal reagents and protocol, assay protocol with more flexible incubation times than any other currently available ELISA method, and quick adoption into the lab due to minimal training, enabling in-house testing.

As of June 14th, 2016, ZEUS Scientific has assumed all the sales, marketing and support functions for all of the AtheNA Multi-Lyte test systems, instruments and consumables for our customers based in the United States. Contact ZEUS directly to find out more about how these multiplex, fluorescent, bead-based assays offer a simple and efficient testing alternative. Be sure that no well is missed with SAVe Diluent(TM), and discover how our proprietary Intra-Well Calibration Technology(R) reduces the number of non-reportable wells in every run to maximize your value in choosing this unique platform!

ZEUS Scientific has been notified by the American Medical Association (AMA) that the Current Procedural Terminology (CPT) Editorial Panel has accepted its request to add code 0423T to report a test for measurement of secretory type II phospholipase A2 (sPLA2-IIA) protein for assessment of level of risk for cardiovascular event. The code has been posted to the AMA CPT website with an effective implementation date of January 1, 2016.

ZEUS Scientific and Gamma Therapeutics announced today that they have signed a new agreement providing ZEUS exclusive, worldwide rights to distribute, market and sell the GammaCoeur CVD Risk ELISA test.

ZEUS Scientific announced today that it has finalized an agreement to purchase all right, title, and interest in the ImmuSTRIP HAMA IgG and ImmuSTRIP® HAMA Fragment ELISA kits from Immunomedics, Inc. (NASDAQ: IMMU).

ZEUS Scientific, a leading in vitro diagnostic solution provider, is pleased to announce the appointment of Wilentz, Goldman & Spitzer P.A. as its corporate counsel.